Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 23 | 2020 | 61 | 3.960 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2020 | 24 | 1.460 |
Why?
|
| Muscle, Skeletal | 9 | 2019 | 520 | 1.070 |
Why?
|
| Charcot-Marie-Tooth Disease | 3 | 2020 | 8 | 1.050 |
Why?
|
| Neural Conduction | 4 | 2020 | 82 | 0.960 |
Why?
|
| Ultrasonography | 9 | 2019 | 393 | 0.870 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 7 | 0.650 |
Why?
|
| Plasma Exchange | 1 | 2020 | 13 | 0.640 |
Why?
|
| Humans | 46 | 2020 | 32274 | 0.620 |
Why?
|
| Mutation | 4 | 2019 | 497 | 0.610 |
Why?
|
| Hemifacial Spasm | 1 | 2019 | 3 | 0.600 |
Why?
|
| Trigeminal Neuralgia | 1 | 2019 | 33 | 0.580 |
Why?
|
| Family Health | 2 | 2017 | 73 | 0.580 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2018 | 1 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 98 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 95 | 0.580 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 9 | 0.580 |
Why?
|
| Nerve Tissue | 1 | 2018 | 4 | 0.570 |
Why?
|
| Middle Aged | 29 | 2020 | 11848 | 0.560 |
Why?
|
| Immunologic Factors | 1 | 2018 | 53 | 0.560 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2017 | 2 | 0.520 |
Why?
|
| Gelsolin | 1 | 2017 | 2 | 0.520 |
Why?
|
| Amyloidosis, Familial | 1 | 2017 | 2 | 0.520 |
Why?
|
| Muscles | 1 | 2017 | 69 | 0.510 |
Why?
|
| Electromyography | 3 | 2017 | 67 | 0.500 |
Why?
|
| Male | 32 | 2020 | 19437 | 0.490 |
Why?
|
| Periventricular Nodular Heterotopia | 1 | 2016 | 1 | 0.490 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2016 | 5 | 0.490 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2016 | 3 | 0.490 |
Why?
|
| Peripheral Nerves | 2 | 2019 | 60 | 0.470 |
Why?
|
| Muscle Cramp | 1 | 2015 | 4 | 0.470 |
Why?
|
| Adult | 23 | 2020 | 9256 | 0.470 |
Why?
|
| Upper Extremity | 1 | 2016 | 68 | 0.460 |
Why?
|
| Female | 31 | 2020 | 19942 | 0.440 |
Why?
|
| Aged | 21 | 2020 | 10260 | 0.420 |
Why?
|
| Brain | 1 | 2020 | 965 | 0.400 |
Why?
|
| Myasthenia Gravis | 2 | 2020 | 15 | 0.380 |
Why?
|
| Autoantibodies | 2 | 2020 | 50 | 0.380 |
Why?
|
| Neuromuscular Junction | 4 | 2018 | 70 | 0.350 |
Why?
|
| Hematoma | 1 | 2011 | 26 | 0.350 |
Why?
|
| Myography | 3 | 2018 | 7 | 0.340 |
Why?
|
| Electric Impedance | 3 | 2018 | 13 | 0.340 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2010 | 1 | 0.330 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 2 | 0.330 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 4 | 0.330 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 46 | 0.330 |
Why?
|
| Stroke | 2 | 2009 | 691 | 0.320 |
Why?
|
| Cranial Nerves | 1 | 2009 | 7 | 0.300 |
Why?
|
| Thromboembolism | 1 | 2009 | 33 | 0.290 |
Why?
|
| Immunity | 2 | 2018 | 19 | 0.290 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 3898 | 0.280 |
Why?
|
| Disease Progression | 6 | 2020 | 591 | 0.270 |
Why?
|
| Motor Neurons | 3 | 2020 | 50 | 0.250 |
Why?
|
| Case-Control Studies | 5 | 2019 | 854 | 0.250 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2006 | 1 | 0.240 |
Why?
|
| Sural Nerve | 2 | 2019 | 25 | 0.230 |
Why?
|
| Blepharoptosis | 1 | 2005 | 1 | 0.230 |
Why?
|
| Neuroprotective Agents | 2 | 2020 | 32 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 18 | 0.230 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 26 | 0.230 |
Why?
|
| Myelin P0 Protein | 2 | 2019 | 4 | 0.230 |
Why?
|
| Adolescent | 5 | 2020 | 3517 | 0.230 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 465 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Median Nerve | 2 | 2017 | 50 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Ceftriaxone | 2 | 2014 | 15 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Cognition Disorders | 1 | 2006 | 349 | 0.190 |
Why?
|
| Research Design | 2 | 2016 | 314 | 0.190 |
Why?
|
| Young Adult | 5 | 2020 | 2648 | 0.180 |
Why?
|
| Evoked Potentials, Motor | 2 | 2018 | 8 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 324 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Plasmapheresis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Agrin | 1 | 2020 | 9 | 0.160 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2020 | 9 | 0.160 |
Why?
|
| Intermediate Filaments | 1 | 2020 | 4 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 94 | 0.160 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 35 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 14 | 0.150 |
Why?
|
| Time Factors | 3 | 2020 | 2204 | 0.150 |
Why?
|
| Inpatients | 1 | 2020 | 83 | 0.150 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2019 | 8 | 0.150 |
Why?
|
| Myositis, Inclusion Body | 1 | 2019 | 7 | 0.150 |
Why?
|
| Pedigree | 1 | 2019 | 136 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2019 | 28 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2018 | 27 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2019 | 224 | 0.140 |
Why?
|
| Sample Size | 1 | 2018 | 38 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.140 |
Why?
|
| Family | 1 | 2019 | 112 | 0.140 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 41 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 137 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1479 | 0.130 |
Why?
|
| Phenotype | 1 | 2019 | 621 | 0.130 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 5 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 69 | 0.130 |
Why?
|
| Extremities | 1 | 2017 | 54 | 0.130 |
Why?
|
| Scapula | 1 | 2017 | 19 | 0.130 |
Why?
|
| Wrist | 1 | 2017 | 44 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 312 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 46 | 0.130 |
Why?
|
| Neuromuscular Agents | 1 | 2017 | 36 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 757 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 27 | 0.120 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2016 | 3 | 0.120 |
Why?
|
| Huntington Disease | 1 | 2016 | 13 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 146 | 0.110 |
Why?
|
| Ulnar Neuropathies | 1 | 2015 | 17 | 0.110 |
Why?
|
| Inflammation | 1 | 2018 | 506 | 0.110 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2015 | 56 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1223 | 0.110 |
Why?
|
| Myelin Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 502 | 0.100 |
Why?
|
| Vital Capacity | 3 | 2018 | 37 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 541 | 0.100 |
Why?
|
| Plant Oils | 1 | 2013 | 17 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 964 | 0.100 |
Why?
|
| African Americans | 1 | 2019 | 1335 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 245 | 0.090 |
Why?
|
| Age of Onset | 2 | 2016 | 90 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 188 | 0.090 |
Why?
|
| Muscular Atrophy | 1 | 2011 | 74 | 0.080 |
Why?
|
| Motor Neuron Disease | 1 | 2010 | 3 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2010 | 13 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2019 | 1840 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 757 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2020 | 565 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2009 | 141 | 0.070 |
Why?
|
| Apoptosis | 1 | 2010 | 375 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2008 | 5 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3624 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 456 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 55 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 26 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 10 | 0.060 |
Why?
|
| Electrodiagnosis | 2 | 2017 | 41 | 0.060 |
Why?
|
| Hearing Loss | 1 | 2006 | 25 | 0.060 |
Why?
|
| Animals | 5 | 2018 | 8199 | 0.060 |
Why?
|
| Epilepsy | 1 | 2006 | 79 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1083 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 893 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 2316 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1158 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2240 | 0.040 |
Why?
|
| Risk Factors | 1 | 2009 | 3934 | 0.040 |
Why?
|
| Time | 1 | 2020 | 27 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 717 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3416 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 101 | 0.040 |
Why?
|
| Forearm | 1 | 2019 | 44 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Diaphragm | 1 | 2018 | 37 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 471 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 955 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 556 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 853 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 16 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2017 | 30 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2017 | 34 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 553 | 0.030 |
Why?
|
| Head | 1 | 2017 | 56 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1534 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 192 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 64 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 97 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2434 | 0.030 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 3 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 101 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 543 | 0.020 |
Why?
|
| United States | 1 | 2020 | 4072 | 0.020 |
Why?
|
| Semaphorins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Growth Cones | 1 | 2010 | 2 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 8 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 14 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 64 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 20 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 128 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 99 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 150 | 0.020 |
Why?
|
| Ganglia, Spinal | 1 | 2010 | 59 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 204 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 288 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 97 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 839 | 0.020 |
Why?
|
| Riluzole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 238 | 0.020 |
Why?
|
| Hindlimb | 1 | 2007 | 53 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 257 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2007 | 137 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 299 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 332 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1179 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 2571 | 0.010 |
Why?
|